ClinicalTrials.gg
CompletedNCT01671839Updated Dec 10, 2019Results posted

Study of the Cabochon System for Improvement in the Appearance of Cellulite

An interventional study of Subcutaneous tissue release with the Cabochon System in Gynoid Lipodystrophy, sponsored by Merz North America, Inc.. Completed at 3 sites in United States. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-10.

Sponsored by Merz North America, Inc. (part of Merz Pharma) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Lipodystrophy with a site in United States — 5 open to participants now, 7 under way, 1 of them phase 3. Lipodystrophy · United States.

Enrollment
21st of 51
55 · median 44
Started
2012
with 3 others
No phase
15 of 77
none open now
Registered
53rd of 77
by date

Among the 77 studies in Lipodystrophy with a site in United States, this one is the 21st largest by enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2012, is one of 15 with no phase, and was the 53rd registered.

Lipodystrophy

140 studies on the registry are indexed under Lipodystrophy; 11 are open to participants now.

Browse Lipodystrophy studies →

Open to participants now

5 of the 77 studies in Lipodystrophy with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Lipodystrophy studies recruiting now, 4 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years to 55 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Lipodystrophy with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of the Cabochon System for the improvement in the appearance of cellulite.

03

Conditions studied

  • Gynoid Lipodystrophy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Female, age 18-55
  • moderate or severe cellulite
  • less than 35
  • will not to try any other cellulite treatments through 12M follow-up

Exclusion Criteria:

  • cellulite treatment on the thighs or buttocks in the last 90 days
  • prior liposuction in the thighs or buttocks
  • Greater than 10% increase or decrease in body weight within past 6 months
  • evidence of active infection or a fever >38C
  • current or recent smoker
  • history of hypertension, diabetes or hypoglycemia
  • history of coagulopathy(ies) and/or on anticoagulant medication
  • history of cardiopathy or pneumopathy
  • history of severe anemia
  • has atrophic scars, or has a history of atrophic scars or keloids
  • taken within 14 days of treatment:

    • NSAIDs (e.g. aspirin, ibuprofen, naproxen)
    • Vitamin E, dietary supplements (e.g. Gingko Biloba, willow bark)
    • Herbal Teas
  • Subject is pregnant or lactating

For Extended Follow-Up the following apply:

Inclusion Criteria:

  • Subject was enrolled and treated in the CP-01-1004 study - Pivotal Study of the Cabochon System for Improvement in the Appearance of Cellulite
  • Subject understands and accepts the obligation not to try or receive any other cellulite treatments through 3 year follow-up

Exclusion Criteria:

  • Subject has undergone an injected drug, energy-based device, minimally-invasive or invasive procedure for contouring or cellulite on the buttocks or thighs since their 12 month study follow-up visit.
  • Subject has used skin care products (e.g. creams) for improvement in cellulite within 1 month prior to the follow-up visit.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Subcutaneous tissue release

    Device: Subcutaneous tissue release with the Cabochon System

    Device: Subcutaneous tissue release with the Cabochon System

Interventions

  • DeviceSubcutaneous tissue release with the Cabochon System

    Device: Subcutaneous tissue release

    Also known as: Cellfina®

06

What researchers measure

Primary outcomes

  1. Mean Change (Decrease) in Cellulite Severity

    Achievement of ≥1 point mean reduction in the 0-5 point Cellulite Severity Scale as determined by independent physician assessment of subject photographs taken before and 3 and 5 years after treatment. Cellulite severity was graded on a 0 (no cellulite) to 5 (severe cellulite) for each subject photograph taken at baseline (before treatment) and 3 and 5 years after treatment by an independent and blinded physician panel. The primary endpoint was achievement of a mean post-treatment severity at 3 and 5 years for the study population which was a minimum of 1 point lower than the baseline severity.

    Time frame: Treatment to 3 and 5 years

Secondary outcomes

  1. Improvement in Cellulite Severity Grade

    Percentage of subjects which were scored to have improvement of one grade or more in a 4 point Severity Grade (none, mild, moderate, severe) as determined by independent blinded physician assessment of subject photographs taken before and 3 and 5 years after treatment.

    Time frame: 3 and 5 years

  2. Improved Appearance

    Improvement in subject's cellulite appearance according to a Global Aesthetic Improvement Scale (GAIS) evaluated by independent and blinded physician panel assessment of subject photographs taken before and 3 and 5 years after treatment. Change in the cellulite severity was rated according to 5 measures: * Very much improved: Optimal cosmetic result in the treated areas for this subject * Much improved: Marked or significant improvement in appearance of the treated areas from the initial condition * Improved: Noticeable improvement in appearance of the treated areas from the initial condition but more subtle in magnitude * No Change: The appearance of the treated areas is essentially the same as the original condition * Worse: The appearance of the treated areas is worse than the original condition

    Time frame: Treatment to 3 and 5 years

  3. Subject Satisfaction

    Subject rated satisfaction according to a 5 point Likert scale after treatment: Very Satisfied Satisfied Neutral Unsatisfied Very Unsatisfied

    Time frame: Treatment to 3 and 5 years

  4. Procedure Tolerability

    Subject rated pain according to a 0-10 numerical rating scale. Pain scale ranges from 0 (no pain) to 10 (worst possible pain). Measure was reported as mean and standard deviation of the pain score

    Time frame: Treatment to 3 and 5 years

  5. Safe Treatment

    Freedom from serious adverse events directly attributable to the Cabochon System or procedure.

    Time frame: Treatment to 3 and 5 years

07

Results

Posted Sep 4, 2014

Participant flow

Participant flow — Overall Study
MilestoneSubcutaneous Tissue Release
Started55
3-year follow-up45
5-year follow-up37
Completed37
Not completed18

Outcome measures

PrimaryMean Change (Decrease) in Cellulite Severity

Achievement of ≥1 point mean reduction in the 0-5 point Cellulite Severity Scale as determined by independent physician assessment of subject photographs taken before and 3 and 5 years after treatment. Cellulite severity was graded on a 0 (no cellulite) to 5 (severe cellulite) for each subject photograph taken at baseline (before treatment) and 3 and 5 years after treatment by an independent and blinded physician panel. The primary endpoint was achievement of a mean post-treatment severity at 3 and 5 years for the study population which was a minimum of 1 point lower than the baseline severity.

Time frame:
Treatment to 3 and 5 years
Reported as:
Mean · units on a scale
Mean Change (Decrease) in Cellulite Severity
units on a scaleSubcutaneous Tissue Release
3 years2.0 (1.7 to 2.3)
5 years1.8 (1.4 to 2.2)
SecondaryImprovement in Cellulite Severity Grade

Percentage of subjects which were scored to have improvement of one grade or more in a 4 point Severity Grade (none, mild, moderate, severe) as determined by independent blinded physician assessment of subject photographs taken before and 3 and 5 years after treatment.

Time frame:
3 and 5 years
Reported as:
Number · percentage of subjects
Improvement in Cellulite Severity Grade
percentage of subjectsSubcutaneous Tissue Release
3 years91.1 (79.3 to 100)
5 years86 (75 to 100)
SecondaryImproved Appearance

Improvement in subject's cellulite appearance according to a Global Aesthetic Improvement Scale (GAIS) evaluated by independent and blinded physician panel assessment of subject photographs taken before and 3 and 5 years after treatment. Change in the cellulite severity was rated according to 5 measures: * Very much improved: Optimal cosmetic result in the treated areas for this subject * Much improved: Marked or significant improvement in appearance of the treated areas from the initial condition * Improved: Noticeable improvement in appearance of the treated areas from the initial condition but more subtle in magnitude * No Change: The appearance of the treated areas is essentially the same as the original condition * Worse: The appearance of the treated areas is worse than the original condition

Time frame:
Treatment to 3 and 5 years
Reported as:
Number · percentage of subjects
Improved Appearance
percentage of subjectsSubcutaneous Tissue Release - 3 YearsSubcutaneous Tissue Release - 5 Years
Very Much Improved8.9 (2.5 to 21.2)5.4 (0.7 to 18.2)
Much Improved46.7 (31.7 to 62.1)29.7 (15.9 to 47.0)
Improved44.4 (29.6 to 60)64.9 (47.5 to 79.8)
No Change0 (0 to 6.9)0 (0 to 9.5)
Worse0 (0 to 6.9)0 (0 to 9.5)
SecondarySubject Satisfaction

Subject rated satisfaction according to a 5 point Likert scale after treatment: Very Satisfied Satisfied Neutral Unsatisfied Very Unsatisfied

Time frame:
Treatment to 3 and 5 years
Reported as:
Number · percentage of subjects
Subject Satisfaction
percentage of subjectsSubcutaneous Tissue Release - 3 YearsSubcutaneous Tissue Release - 5 Years
% Very Satisfied42.2 (27.7 to 57.9)46.0 (29.5 to 63.1)
% Satisfied51.1 (35.8 to 66.3)32.4 (18.0 to 49.8)
% Neutral6.7 (1.4 to 18.3)18.9 (8.0 to 35.2)
% Unsatisfied0 (0 to 6.8)0 (0 to 9.5)
% Very Unsatisfied0 (0 to 6.8)0 (0 to 9.5)
SecondaryProcedure Tolerability

Subject rated pain according to a 0-10 numerical rating scale. Pain scale ranges from 0 (no pain) to 10 (worst possible pain). Measure was reported as mean and standard deviation of the pain score

Time frame:
Treatment to 3 and 5 years
Reported as:
Mean · units on scale
Procedure Tolerability
units on scaleSubcutaneous Tissue Release - 3 YearsSubcutaneous Tissue Release - 5 Years
Procedure Tolerability0 ± 00 ± 0
SecondarySafe Treatment

Freedom from serious adverse events directly attributable to the Cabochon System or procedure.

Time frame:
Treatment to 3 and 5 years
Reported as:
Number · occurence of serious adverse events
Safe Treatment
occurence of serious adverse eventsSubcutaneous Tissue Release - 3 YearsSubcutaneous Tissue Release - 5 Years
Safe Treatment00

Adverse events

Collected over From baseline up to year 5.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Subcutaneous Tissue Release - 3 Years0/55 (0%)0/55 (0%)4/55 (7.3%)
Subcutaneous Tissue Release - Years 4-50/37 (0%)0/37 (0%)0/37 (0%)
Most frequent other events
Most frequent other events
EventSubcutaneous Tissue Release - 3 YearsSubcutaneous Tissue Release - Years 4-5
ColdInfections and infestations2/550/37
DiarrheaGastrointestinal disorders2/550/37
HypercholesterolemiaMetabolism and nutrition disorders2/55—

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Subcutaneous Tissue Release
Mean40.7 ± 9.1
Sex: Female, Male
Sex: Female, Male(Participants)Subcutaneous Tissue Release
Female55
Male0
08

Study locations

3 sites
  • The Coleman Center for Cosmetic and Dermatologic Surgery
    Metairie, Louisiana 70006, United States
  • Maryland Laser Skin & Vein Institute
    Hunt Valley, Maryland 21030, United States
  • SkinCare Physicians
    Chestnut Hill, Massachusetts 02467, United States
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2012, a primary completion of Sep 2013 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2012
First posted
Aug 24, 2012
Start
Aug 2012
Primary completionActual
Sep 2013
CompletionActual
Dec 2015
Results first posted
Sep 4, 2014
Last update
Dec 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01671839
Collaborators
Ulthera, Inc
Responsible party
Sponsor
First posted
Aug 24, 2012
Start date
Aug 2012
Primary completion
Sep 2013
Completion
Dec 2015
Results posted
Sep 4, 2014
Last update
Dec 10, 2019

Study contacts

Michael S Kaminer
principal investigator · Skin Care Physicians

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion